Rose McCormack

3.3k total citations · 1 hit paper
11 papers, 2.0k citations indexed

About

Rose McCormack is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Rose McCormack has authored 11 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Rose McCormack's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Rose McCormack is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (7 papers) and Lung Cancer Diagnosis and Treatment (4 papers). Rose McCormack collaborates with scholars based in United Kingdom, China and Japan. Rose McCormack's co-authors include Simon Dearden, Anita Midha, Guanshan Zhu, Gillian Ellison, Georgina Speake, Gael McWalter, Tsveta Milenkova, Tudor–Eliade Ciuleanu, Jean‐Yves Douillard and Gyula Ostoros and has published in prestigious journals such as Journal of Clinical Pathology, Drug Discovery Today and Journal of Thoracic Oncology.

In The Last Decade

Rose McCormack

11 papers receiving 2.0k citations

Hit Papers

EGFR mutation incidence in non-small-cell lung cancer of ... 2015 2026 2018 2022 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).
    2015 655 citations Anita Midha, Simon Dearden et al. PubMed profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rose McCormack United Kingdom 11 1.7k 1.1k 1.1k 444 207 11 2.0k
Simon Dearden United Kingdom 16 2.0k 1.2× 1.2k 1.1× 1.4k 1.3× 761 1.7× 258 1.2× 30 2.6k
Michèle Beau‐Faller France 22 1.6k 0.9× 554 0.5× 1.3k 1.2× 758 1.7× 156 0.8× 61 2.1k
Jianchun Duan China 23 1.1k 0.6× 673 0.6× 1.0k 0.9× 511 1.2× 139 0.7× 96 1.7k
Tongtong An China 23 1.1k 0.6× 620 0.6× 912 0.9× 527 1.2× 128 0.6× 90 1.6k
Xiaoqing Liu China 19 1.0k 0.6× 462 0.4× 916 0.9× 407 0.9× 123 0.6× 70 1.5k
Nora Feeney United States 8 1.1k 0.7× 959 0.9× 772 0.7× 516 1.2× 245 1.2× 11 1.5k
Liza C. Villaruz United States 23 1.2k 0.7× 422 0.4× 1.3k 1.2× 675 1.5× 228 1.1× 81 2.0k
Felice Mucilli Italy 16 1.5k 0.9× 464 0.4× 1.1k 1.0× 756 1.7× 139 0.7× 59 2.0k
Shang‐Gin Wu Taiwan 29 1.9k 1.1× 683 0.6× 1.5k 1.4× 955 2.2× 160 0.8× 64 2.6k
Georgina Speake United Kingdom 11 1.8k 1.1× 532 0.5× 1.5k 1.4× 583 1.3× 84 0.4× 16 2.3k

Countries citing papers authored by Rose McCormack

Since Specialization
Citations

This map shows the geographic impact of Rose McCormack's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rose McCormack with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rose McCormack more than expected).

Fields of papers citing papers by Rose McCormack

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rose McCormack. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rose McCormack. The network helps show where Rose McCormack may publish in the future.

Co-authorship network of co-authors of Rose McCormack

This figure shows the co-authorship network connecting the top 25 collaborators of Rose McCormack. A scholar is included among the top collaborators of Rose McCormack based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rose McCormack. Rose McCormack is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Han, Baohui, Sergei Tjulandin, Koichi Hagiwara, et al.. (2017). EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer. 113. 37–44. 113 indexed citations
2.
Reck, Martin, Koichi Hagiwara, Baohui Han, et al.. (2016). ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study. Journal of Thoracic Oncology. 11(10). 1682–1689. 131 indexed citations
3.
Zhu, Guanshan, Xin Ye, Zhengwei Dong, et al.. (2015). Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer. Journal of Molecular Diagnostics. 17(3). 265–272. 161 indexed citations
4.
Midha, Anita, Simon Dearden, & Rose McCormack. (2015). EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).. PubMed. 5(9). 2892–911. 655 indexed citations breakdown →
5.
Douillard, Jean‐Yves, Gyula Ostoros, Manuel Cobo, et al.. (2014). Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status. Journal of Thoracic Oncology. 9(9). 1345–1353. 348 indexed citations
6.
Liu, Xiaoqing, Yachao Lu, Guanshan Zhu, et al.. (2013). The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies. Journal of Clinical Pathology. 66(12). 1065–1069. 125 indexed citations
7.
Yang, James Chih‐Hsin, Yi‐Long Wu, Valorie F. Chan, et al.. (2013). Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 83(2). 174–181. 36 indexed citations
8.
Ellison, Gillian, et al.. (2012). EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. Journal of Clinical Pathology. 66(2). 79–89. 235 indexed citations
9.
Goto, Kōichi, Yukito Ichinose, Yuichiro Ohe, et al.. (2011). Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(1). 115–121. 173 indexed citations
10.
Hodgson, Darren, Robert Wellings, Maria Orr, et al.. (2010). Circulating tumour-derived predictive biomarkers in oncology. Drug Discovery Today. 15(3-4). 98–101. 23 indexed citations
11.
Hickinson, D. Mark, Gayle Marshall, Garry Beran, et al.. (2009). Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib. Clinical and Translational Science. 2(3). 183–192. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Simon Dearden Breakdown of academic impact, for papers by Michèle Beau‐Faller Breakdown of academic impact, for papers by Jianchun Duan Breakdown of academic impact, for papers by Tongtong An Breakdown of academic impact, for papers by Xiaoqing Liu Breakdown of academic impact, for papers by Nora Feeney Breakdown of academic impact, for papers by Liza C. Villaruz Breakdown of academic impact, for papers by Felice Mucilli Breakdown of academic impact, for papers by Shang‐Gin Wu Breakdown of academic impact, for papers by Georgina Speake
Rankless by CCL
2026